- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:protocol:olmesartan:kidney_disease [10.13.2018] – [Animal studies] sallieq | home:protocol:olmesartan:kidney_disease [10.25.2018] – [Benefits of angiotensin receptor blockers] sallieq | ||
|---|---|---|---|
| Line 84: | Line 84: | ||
| Olmesartan also has [[home: | Olmesartan also has [[home: | ||
| - | {{tag> | + | {{tag> |
| ==== Animal studies ==== | ==== Animal studies ==== | ||
| Line 93: | Line 93: | ||
| Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pubmed> | Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pubmed> | ||
| - | {{tag> | + | {{tag> |
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| - | --- //Sallie Q 02.03.2017// | ||
| * Legacy content | * Legacy content | ||
home/protocol/olmesartan/kidney_disease.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.